PE20050050A1 - Derivados de indolilo - Google Patents
Derivados de indoliloInfo
- Publication number
- PE20050050A1 PE20050050A1 PE2003000917A PE2003000917A PE20050050A1 PE 20050050 A1 PE20050050 A1 PE 20050050A1 PE 2003000917 A PE2003000917 A PE 2003000917A PE 2003000917 A PE2003000917 A PE 2003000917A PE 20050050 A1 PE20050050 A1 PE 20050050A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- oxazol
- indol
- cycloalkyl
- phenyl
- Prior art date
Links
- -1 INDOLYL Chemical class 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940086609 Lipase inhibitor Drugs 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 abstract 1
- 229960001243 orlistat Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
REFERIDA A UN COMPUESTO DE FORMULA I, DONDE R1 ES ARILO O HETEROARILO; R2 H, ALQUILO, CICLOALQUILO; R3 ES ARILOXILO, ALQUENILOXILO, ALCOXILO, ENTRE OTROS; R4 ES H, ALQUILO, CICLOALQUILO; R5, R6, R7 Y R8 SON CADA UNO H, ALQUILO, CICLOALQUILO; n ES 1-3; A Y A1 ES N Y EL OTRO ES O O S. SON COMPUESTOS PREFERIDOS: ACIDO (S)-3-{1-[2-(2-CLORO-FENIL)-5-METIL-OXAZOL-4-ILMETIL]-1H-INDOL-5-IL}-2-ETOXI-PROPIONICO; ACIDO RAC-2-ETOXI-3-{3-METIL-1-[5-METIL-2-(4-TRIFLUORO-METIL-FENIL)-OXAZOL-4-ILMETIL]-1H-INDOL-5-IL}-PROPIONICO Y ACIDO RAC-3-{1-[5-METIL-2-(4-TRIFLUOROMETIL-FENIL)-OXAZOL-4-ILMETIL]-1H-INDOL-5-IL}-2-PROPOXI-PROPIONICO; ENTRE OTROS. TAMBIEN REFERIDO A SU COMPOSICION FARMACEUTICA QUE ADEMAS COMPRENDE UN INHIBIDOR DE LIPASAS COMO ORLISTAT LA QUE ES UTIL EN CASOS DE DIABETES, SINDROME METABOLICO Y ENFERMEDADES ATEROSCLEROTICAS, ENTRE OTRAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02020477 | 2002-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050050A1 true PE20050050A1 (es) | 2005-02-18 |
Family
ID=31985028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2003000917A PE20050050A1 (es) | 2002-09-12 | 2003-09-10 | Derivados de indolilo |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6890947B2 (es) |
| EP (1) | EP1539746B1 (es) |
| JP (1) | JP4286782B2 (es) |
| KR (1) | KR100645684B1 (es) |
| CN (1) | CN100577660C (es) |
| AR (1) | AR041218A1 (es) |
| AT (1) | ATE345340T1 (es) |
| AU (1) | AU2003267041B2 (es) |
| BR (1) | BR0314261A (es) |
| CA (1) | CA2494601C (es) |
| DE (1) | DE60309719T2 (es) |
| DK (1) | DK1539746T3 (es) |
| ES (1) | ES2275105T3 (es) |
| GT (1) | GT200300194A (es) |
| HR (1) | HRP20050212A2 (es) |
| MX (1) | MXPA05002704A (es) |
| MY (1) | MY135646A (es) |
| NO (1) | NO20050667L (es) |
| NZ (1) | NZ537979A (es) |
| PA (1) | PA8581701A1 (es) |
| PE (1) | PE20050050A1 (es) |
| PL (1) | PL375878A1 (es) |
| PT (1) | PT1539746E (es) |
| RU (1) | RU2296759C2 (es) |
| SI (1) | SI1539746T1 (es) |
| TW (1) | TWI248933B (es) |
| UY (1) | UY27975A1 (es) |
| WO (1) | WO2004024726A1 (es) |
| ZA (1) | ZA200501273B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10022925A1 (de) * | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
| JP2006523698A (ja) * | 2003-04-17 | 2006-10-19 | カリプシス・インコーポレーテッド | Ｐｐａｒ変調薬としての（３−｛３−（２，４−ビス−トリフルオロメチル−ベンジル）−（５−エチル−ピリミジン−２−イル）−アミノ−プロポキシ｝−フェニル）−酢酸および関連化合物、ならびに代謝性障害の処置方法 |
| US20050203151A1 (en) * | 2003-12-19 | 2005-09-15 | Kalypsys, Inc. | Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions |
| US7405236B2 (en) * | 2004-08-16 | 2008-07-29 | Hoffman-La Roche Inc. | Indole derivatives comprising an acetylene group |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| NO20083270L (no) * | 2008-07-23 | 2010-01-25 | Thia Medica As | Indolforbindelser |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4011326A (en) | 1975-07-29 | 1977-03-08 | Merck & Co., Inc. | 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents |
| DK151884C (da) * | 1979-03-07 | 1988-06-13 | Pfizer | Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| EP1000938A1 (en) | 1992-07-03 | 2000-05-17 | Smithkline Beecham Plc | Heterocyclic compounds as pharmaceuticals |
| GB9225386D0 (en) | 1992-12-04 | 1993-01-27 | Smithkline Beecham Plc | Novel compounds |
| DE4317320A1 (de) | 1993-05-25 | 1994-12-01 | Boehringer Mannheim Gmbh | Neue Thiazolidindione und diese enthaltende Arzneimittel |
| GB9326171D0 (en) | 1993-12-22 | 1994-02-23 | Smithkline Beecham Plc | Novel compounds |
| IL117208A0 (en) * | 1995-02-23 | 1996-06-18 | Nissan Chemical Ind Ltd | Indole type thiazolidines |
| WO1996032379A1 (en) * | 1995-04-10 | 1996-10-17 | Fujisawa Pharmaceutical Co., Ltd. | INDOLE DERIVATIVES AS cGMP-PDE INHIBITORS |
| JPH09176162A (ja) * | 1995-12-22 | 1997-07-08 | Toubishi Yakuhin Kogyo Kk | チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物 |
| GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
| ES2217392T3 (es) * | 1996-02-02 | 2004-11-01 | MERCK & CO., INC. | Agentes antidiabeticos. |
| WO1998025606A1 (en) | 1996-12-10 | 1998-06-18 | Bristol-Myers Squibb Company | Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents |
| US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| DE19711616A1 (de) | 1997-03-20 | 1998-09-24 | Boehringer Mannheim Gmbh | Verbessertes Verfahren zur Herstellung von Thiazolidindionen |
| US6121397A (en) | 1997-07-14 | 2000-09-19 | Xerox Corporation | Polymerization processes using oligomeric compound, monomer and surfactant |
| HN1998000118A (es) | 1997-08-27 | 1999-02-09 | Pfizer Prod Inc | 2 - aminopiridinas que contienen sustituyentes de anillos condensados. |
| EP0903343B1 (en) | 1997-09-19 | 2003-05-28 | SSP Co., Ltd. | Alpha-Substituted phenylpropionic acid derivative and medicine containing the same |
| EP1073643B1 (en) | 1998-04-23 | 2004-12-29 | Dr. Reddy's Laboratories Ltd. | New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| GB9817118D0 (en) | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| AU759388B2 (en) | 1998-08-14 | 2003-04-10 | Cheplapharm Arzneimittel Gmbh | Pharmaceutical compositions containing lipase inhibitors and chitosan |
| TR200100471T2 (tr) | 1998-08-14 | 2001-07-23 | F.Hoffmann-La Roche Ag | Lipaz inhibitörleri içeren farmasötik bileşimler |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| DE60026404T2 (de) | 1999-08-02 | 2006-10-19 | F. Hoffmann-La Roche Ag | Verfahren zur Herstellung von Benzothiophen-Derivaten |
| WO2002008188A1 (en) * | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | N-substituted indoles useful in the treatment of diabetes |
| AU2001284659A1 (en) | 2000-08-23 | 2002-03-04 | Eli Lilly And Company | Oxazolyl-arylpropionic acid derivatives and their use as PPAR agonists |
| DE10117090B4 (de) * | 2001-04-06 | 2013-08-14 | Dr. Ing. H.C. F. Porsche Aktiengesellschaft | Wassergekühlte, mehrzylindrige Brennkraftmaschine |
| WO2003005025A1 (en) | 2001-07-03 | 2003-01-16 | Biovitrum Ab | Methods for identifying compounds modulating the activity of ppar-gamma |
| US6673815B2 (en) * | 2001-11-06 | 2004-01-06 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| WO2003053976A1 (en) | 2001-12-20 | 2003-07-03 | Biovitrum Ab | PIPAZOLO [1,5-a] PYRIMIDINE DERIVATIVES AS MODULATORS OF PPAR |
-
2003
- 2003-09-04 JP JP2004535427A patent/JP4286782B2/ja not_active Expired - Fee Related
- 2003-09-04 MX MXPA05002704A patent/MXPA05002704A/es active IP Right Grant
- 2003-09-04 PL PL03375878A patent/PL375878A1/xx not_active Application Discontinuation
- 2003-09-04 DK DK03747962T patent/DK1539746T3/da active
- 2003-09-04 AT AT03747962T patent/ATE345340T1/de not_active IP Right Cessation
- 2003-09-04 EP EP03747962A patent/EP1539746B1/en not_active Expired - Lifetime
- 2003-09-04 CN CN03821483A patent/CN100577660C/zh not_active Expired - Fee Related
- 2003-09-04 PT PT03747962T patent/PT1539746E/pt unknown
- 2003-09-04 BR BR0314261-2A patent/BR0314261A/pt not_active IP Right Cessation
- 2003-09-04 DE DE60309719T patent/DE60309719T2/de not_active Expired - Lifetime
- 2003-09-04 CA CA002494601A patent/CA2494601C/en not_active Expired - Fee Related
- 2003-09-04 AU AU2003267041A patent/AU2003267041B2/en not_active Ceased
- 2003-09-04 RU RU2005110921/04A patent/RU2296759C2/ru not_active IP Right Cessation
- 2003-09-04 HR HR20050212A patent/HRP20050212A2/hr not_active Application Discontinuation
- 2003-09-04 SI SI200330631T patent/SI1539746T1/sl unknown
- 2003-09-04 ES ES03747962T patent/ES2275105T3/es not_active Expired - Lifetime
- 2003-09-04 KR KR1020057004166A patent/KR100645684B1/ko not_active Expired - Fee Related
- 2003-09-04 WO PCT/EP2003/009819 patent/WO2004024726A1/en not_active Ceased
- 2003-09-04 NZ NZ537979A patent/NZ537979A/en unknown
- 2003-09-08 TW TW092124737A patent/TWI248933B/zh not_active IP Right Cessation
- 2003-09-09 PA PA20038581701A patent/PA8581701A1/es unknown
- 2003-09-10 US US10/659,664 patent/US6890947B2/en not_active Expired - Fee Related
- 2003-09-10 PE PE2003000917A patent/PE20050050A1/es not_active Application Discontinuation
- 2003-09-10 GT GT200300194A patent/GT200300194A/es unknown
- 2003-09-10 AR ARP030103266A patent/AR041218A1/es unknown
- 2003-09-10 MY MYPI20033416A patent/MY135646A/en unknown
- 2003-09-11 UY UY27975A patent/UY27975A1/es not_active Application Discontinuation
-
2005
- 2005-02-08 NO NO20050667A patent/NO20050667L/no not_active Application Discontinuation
- 2005-02-11 ZA ZA200501273A patent/ZA200501273B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050050A1 (es) | Derivados de indolilo | |
| PE20050948A1 (es) | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv | |
| PE20120834A1 (es) | Derivados de furopirimidindiona como moduladores de trpa1 | |
| PE20050018A1 (es) | Compuesto pentaciclico heteroaromatico como inhibidor de la proteina tirosina fosfatasa 1b (ptb1b) | |
| PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
| PE20050690A1 (es) | Derivados de indazol como inhibidores de la lipasa sensible a hormonas | |
| PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
| AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
| PE20040589A1 (es) | Tiazolidinonas y su preparacion como medicamentos | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| PE20040687A1 (es) | Quinolinas sustituidas como antagonistas del receptor ccr5 | |
| PE20070121A1 (es) | 2,4-diamino-pirimidinas como inhibidores de aurora | |
| PE20080155A1 (es) | Compuestos heterociclicos como inhibidores de aspartil-proteasa | |
| PE20090641A1 (es) | Amidas heterociclicas | |
| ES2572148T3 (es) | Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados | |
| PE20050872A1 (es) | Compuestos 5-fenil-tiazol-2-il-amida como inhibidores de la enzima fosfatidilinositol 3-cinasa | |
| PE20081836A1 (es) | Derivados de piperidina como inhibidores de la sintasa de acido graso | |
| ECSP056016A (es) | Nuevos derivados de 2-piridinacarboxamida | |
| UY28121A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos | |
| PE20081344A1 (es) | Inhibidores del virus de la hepatitis c | |
| ECSP12006640A (es) | Inhibidores heterocíclicos de aspartil proteasa | |
| PE20070531A1 (es) | Compuestos heterociclicos como inhibidores de aspartil proteasas | |
| AR039399A1 (es) | Compuestos quimicos con actividad doble, procedimientos para su preparacion y composiciones farmaceuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |